Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug could save lives from shock after severe bleeding

NCT ID NCT05956418

Disease control Sponsor: Pharmazz, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called LYFAQUIN (centhaquine) for people in hypovolemic shock, a life-threatening condition caused by severe blood or fluid loss. The drug aims to help restore blood pressure and improve survival when used alongside standard treatments. About 400 adults in the emergency room or ICU will take part to check safety and how well it works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2021

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria • Adult hypovolemic shock patients aged 18 years or older admitted to the emergency room or ICU with systolic blood pressure ≤ 90 mmHg at presentation and continue to receive standard shock treatment. Blood Lactate level indicative of hypovolemic shock (\>2.0 mmol/L). Exclusion Criteria * Development of any other terminal illness not associated with hypovolemic shock during the study duration. * Patient with altered consciousness not due to hypovolemic shock and comatose patient. • Known pregnancy. * Cardiopulmonary resuscitation (CPR) before enrollment. * Presence of a do not resuscitate order. * Patient is participating in another interventional study. * Patients with systemic diseases which were already present before having trauma, such as sepsis, cancer, chronic renal failure, liver failure, decompensated heart failure, or AIDS.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypovolemic shock are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hemorrhage Hypovolemia Shock

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypovolemic shock

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    17 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • ACSR Government Medical College and Hospital

    RECRUITING

    Nellore, Andhra Pradesh, 524004, India

  • All India Institute of Medical Sciences (AIIMS)

    RECRUITING

    Raipur, Chhattisgarh, 492099, India

  • Aman Hospital

    RECRUITING

    Vadodara, Gujarat, 390021, India

  • Christian Medical College and Hospital (CMC)

    RECRUITING

    Ludhiana, Punjab, 141008, India

  • Dayanand Medical College & Hospital (DMCH)

    RECRUITING

    Ludhiana, Punjab, 141001, India

  • Ganesh Shankar Vidyarthi Memorial Medical College (GSVM)

    RECRUITING

    Kanpur, Uttar Pradesh, 208002, India

  • Government Medical College

    RECRUITING

    Kota, Rajasthan, 324010, India

  • IPGMER & SSKM Hospital

    RECRUITING

    Kolkata, West Bengal, 700020,, India

  • Janta Hospital

    RECRUITING

    Varanasi, Uttar Pradesh, 221005, India

  • KG Hospital

    RECRUITING

    Coimbatore, Tamil Nadu, 641018, India

  • Maharani Laxmi Bai Medical College (MLBMC)

    RECRUITING

    Jhānsi, Uttar Pradesh, 284001, India

  • Meditrina Hospital

    RECRUITING

    Nagpur, Maharashtra, 440012, India

  • New Era Hospital

    RECRUITING

    Nagpur, Maharashtra, 440008, India

  • Nirmal Hospital

    RECRUITING

    Jhānsi, Uttar Pradesh, 284128, India

  • Pushpanjali Hospital

    RECRUITING

    Agra, Uttar Pradesh, 282002, India

  • Seven Star Hospital

    RECRUITING

    Nagpur, Maharashtra, 440009, India

  • Sri Guru Ram Das University of Health Sciences (SGRDH)

    RECRUITING

    Amritsar, Punjab, 143501, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.